Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.24
AXGN's Cash-to-Debt is ranked lower than
59% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. AXGN: 1.24 )
Ranked among companies with meaningful Cash-to-Debt only.
AXGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11  Med: 5.11 Max: No Debt
Current: 1.24
Equity-to-Asset 0.32
AXGN's Equity-to-Asset is ranked lower than
82% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. AXGN: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
AXGN' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.23  Med: 0.58 Max: 0.91
Current: 0.32
-4.23
0.91
Piotroski F-Score: 4
Altman Z-Score: 3.93
Beneish M-Score: -2.22
WACC vs ROIC
1.42%
-91.41%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -19.78
AXGN's Operating Margin % is ranked lower than
68% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.84 vs. AXGN: -19.78 )
Ranked among companies with meaningful Operating Margin % only.
AXGN' s Operating Margin % Range Over the Past 10 Years
Min: -1447.95  Med: -94.53 Max: 64.05
Current: -19.78
-1447.95
64.05
Net Margin % -35.06
AXGN's Net Margin % is ranked lower than
72% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. AXGN: -35.06 )
Ranked among companies with meaningful Net Margin % only.
AXGN' s Net Margin % Range Over the Past 10 Years
Min: -1426.03  Med: -127.71 Max: 60.4
Current: -35.06
-1426.03
60.4
ROE % -226.21
AXGN's ROE % is ranked lower than
94% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. AXGN: -226.21 )
Ranked among companies with meaningful ROE % only.
AXGN' s ROE % Range Over the Past 10 Years
Min: -581  Med: -124.68 Max: 264.57
Current: -226.21
-581
264.57
ROA % -40.24
AXGN's ROA % is ranked lower than
74% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.21 vs. AXGN: -40.24 )
Ranked among companies with meaningful ROA % only.
AXGN' s ROA % Range Over the Past 10 Years
Min: -128.2  Med: -57.42 Max: 173.62
Current: -40.24
-128.2
173.62
ROC (Joel Greenblatt) % -99.09
AXGN's ROC (Joel Greenblatt) % is ranked lower than
69% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 4.32 vs. AXGN: -99.09 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AXGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -35233.33  Med: -277.41 Max: 265933.33
Current: -99.09
-35233.33
265933.33
3-Year Revenue Growth Rate 18.20
AXGN's 3-Year Revenue Growth Rate is ranked higher than
86% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. AXGN: 18.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AXGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -74.3  Med: -17.7 Max: 471.3
Current: 18.2
-74.3
471.3
3-Year EBITDA Growth Rate -28.90
AXGN's 3-Year EBITDA Growth Rate is ranked lower than
91% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 5.60 vs. AXGN: -28.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AXGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.9  Med: -18.2 Max: 197.7
Current: -28.9
-47.9
197.7
3-Year EPS without NRI Growth Rate -24.20
AXGN's 3-Year EPS without NRI Growth Rate is ranked lower than
81% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. AXGN: -24.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AXGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.5  Med: -15.7 Max: 259.3
Current: -24.2
-50.5
259.3
GuruFocus has detected 4 Warning Signs with AxoGen Inc $AXGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AXGN's 10-Y Financials

Financials (Next Earnings Date: 2017-05-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AXGN Guru Trades in Q1 2016

Jim Simons Sold Out
» More
Q2 2016

AXGN Guru Trades in Q2 2016

Jim Simons 174,700 sh (New)
» More
Q3 2016

AXGN Guru Trades in Q3 2016

Chuck Royce 20,000 sh (New)
Jim Simons 126,900 sh (-27.36%)
» More
Q4 2016

AXGN Guru Trades in Q4 2016

Chuck Royce Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AXGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NAS:TCMD, NYSE:IVC, NAS:ELOS, NAS:EXAC, NAS:CUTR, NAS:ARAY, AMEX:CVRS, NAS:RTIX, OTCPK:IPDQF, NAS:VRAY, NAS:XENT, NAS:OBLN, NAS:PAVM, OTCPK:NMRD, NAS:IRIX, NAS:ACRX, NAS:NVCN, NAS:FONR, NAS:CGNT, NAS:DRAD » details
Traded in other countries:LT3.Germany,
AxoGen Inc is a regenerative medicine company. The Company has a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration.

AxoGen Inc is a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves the Company has developed and licensed technologies which are used in its products. Its product portfolio includes Avance Nerve Graft, which the Company believes is the first and only commercially available processed allograft nerve for bridging nerve discontinuities. AxoGuard Nerve Connector, is used as a coaptation aid to facilitate the tensionless repair of severed nerves, and AxoGuard Nerve Protector is used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. The Company's products are used by surgeons during surgical interventions to repair a wide variety of nerve injuries throughout the body. These injuries range from a simple laceration of a finger to a complex brachial plexus injury (an injury to the network of nerves that originate in the neck) as well as nerve injuries caused by dental and other surgical procedures. Avance Nerve Graft provides surgeons bridging material with the micro-architecture of a human nerve. This structure is essential and allows for bridging nerve gaps or discontinuities up to 70mm in length. Additionally, Avance Nerve Graft has product and sales synergies with AxoGuard Nerve Protector and AxoGuard Nerve Connector. AxoGuard products provide the unique features of pliability, suturability, and translucence for visualization of the underlying nerve, while also allowing the patient's own cells to incorporate into the extracellular matrix to remodel and form a tissue similar to the outermost layer of the nerve (nerve epineurium). Regenerative medical products enable the repair, restoration, replacement or regeneration of tissue or organ systems of the body. Regenerative medical products are becoming common in various medical arenas because they have been shown to be effective repairing injured or defective tissues, such as bone, tendons, dermis and other tissues of the body. AxoGen's products are subject to regulation by the FDA, as well as other federal and state regulatory bodies in the U.S. and comparable authorities in other countries.

Ratios

vs
industry
vs
history
PB Ratio 22.26
AXGN's PB Ratio is ranked lower than
98% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 3.37 vs. AXGN: 22.26 )
Ranked among companies with meaningful PB Ratio only.
AXGN' s PB Ratio Range Over the Past 10 Years
Min: 0.69  Med: 12.64 Max: 607.5
Current: 22.26
0.69
607.5
PS Ratio 7.44
AXGN's PS Ratio is ranked lower than
78% of the 329 Companies
in the Global Medical Devices industry.

( Industry Median: 3.34 vs. AXGN: 7.44 )
Ranked among companies with meaningful PS Ratio only.
AXGN' s PS Ratio Range Over the Past 10 Years
Min: 0.48  Med: 4.55 Max: 833.33
Current: 7.44
0.48
833.33
Current Ratio 3.97
AXGN's Current Ratio is ranked higher than
74% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. AXGN: 3.97 )
Ranked among companies with meaningful Current Ratio only.
AXGN' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 4.38 Max: 12.36
Current: 3.97
0.56
12.36
Quick Ratio 3.48
AXGN's Quick Ratio is ranked higher than
78% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. AXGN: 3.48 )
Ranked among companies with meaningful Quick Ratio only.
AXGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.35  Med: 3.53 Max: 10.61
Current: 3.48
0.35
10.61
Days Inventory 267.14
AXGN's Days Inventory is ranked lower than
82% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 124.59 vs. AXGN: 267.14 )
Ranked among companies with meaningful Days Inventory only.
AXGN' s Days Inventory Range Over the Past 10 Years
Min: 251.85  Med: 275.52 Max: 489.83
Current: 267.14
251.85
489.83
Days Sales Outstanding 71.49
AXGN's Days Sales Outstanding is ranked lower than
54% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 67.79 vs. AXGN: 71.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
AXGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.47  Med: 62.74 Max: 365
Current: 71.49
0.47
365
Days Payable 106.84
AXGN's Days Payable is ranked higher than
76% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. AXGN: 106.84 )
Ranked among companies with meaningful Days Payable only.
AXGN' s Days Payable Range Over the Past 10 Years
Min: 106.84  Med: 167.05 Max: 256.21
Current: 106.84
106.84
256.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -23.80
AXGN's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. AXGN: -23.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AXGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -59  Med: -1.2 Max: 0.7
Current: -23.8
-59
0.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 26.58
AXGN's Price-to-Net-Current-Asset-Value is ranked lower than
90% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 6.87 vs. AXGN: 26.58 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AXGN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.5  Med: 5.34 Max: 45.83
Current: 26.58
1.5
45.83
Price-to-Tangible-Book 23.49
AXGN's Price-to-Tangible-Book is ranked lower than
93% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 4.36 vs. AXGN: 23.49 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AXGN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.35  Med: 2.71 Max: 43.65
Current: 23.49
1.35
43.65
Price-to-Median-PS-Value 1.63
AXGN's Price-to-Median-PS-Value is ranked lower than
79% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. AXGN: 1.63 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AXGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.06  Med: 0.47 Max: 34.38
Current: 1.63
0.06
34.38
Earnings Yield (Greenblatt) % -2.48
AXGN's Earnings Yield (Greenblatt) % is ranked lower than
57% of the 415 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. AXGN: -2.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AXGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.5  Med: 234.1 Max: 33220.9
Current: -2.48
-2.5
33220.9

More Statistics

Revenue (TTM) (Mil) $41.11
EPS (TTM) $ -0.47
Beta-0.37
Short Percentage of Float7.35%
52-Week Range $4.90 - 11.25
Shares Outstanding (Mil)33.01

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 58 79 106
EPS ($) -0.29 -0.07 0.08
EPS without NRI ($) -0.29 -0.07 0.08
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AXGN

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: AxoGen Inc, Medley Capital Corp, Quantum Fuel Systems Technologies Worldw Dec 20 2014 

More From Other Websites
AxoGen, Inc. :AXGN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
AxoGen, Inc. :AXGN-US: Earnings Analysis: 2016 By the Numbers : March 10, 2017 Mar 10 2017
AXOGEN, INC. Financials Mar 07 2017
AxoGen, Inc. to Present at the Oppenheimer 27th Annual Healthcare Conference Mar 07 2017
AxoGen, Inc. breached its 50 day moving average in a Bearish Manner : AXGN-US : March 6, 2017 Mar 06 2017
Coverage initiated on AxoGen by ROTH Capital Mar 06 2017
AxoGen, Inc. to Present at Upcoming Investor Conferences Mar 02 2017
AXOGEN, INC. Files SEC form 10-K, Annual Report Mar 01 2017
AXOGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 22 2017
AxoGen reports 4Q loss Feb 22 2017
AxoGen reports 4Q loss Feb 22 2017
AxoGen, Inc. Reports 2016 Fourth Quarter and Full Year Financial Results Feb 22 2017
AxoGen, Inc. to Report Fourth Quarter and 2016 Full Year Financial Results and Host Conference Call... Feb 08 2017
AXOGEN, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Jan 26 2017
Zacks.com featured highlights: AxoGen, MAG Silver, Triumph Bancorp, UCP and Yelp Jan 18 2017
AXOGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jan 09 2017
AxoGen, Inc. Preannounces Estimated Fourth Quarter and Full Year 2016 Revenue Jan 09 2017
AxoGen Appoints Ivica Ducic Medical Director Jan 05 2017
AxoGen Appoints Ivica Ducic Medical Director Jan 05 2017
AXOGEN, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)